Drug Trial Radar · NCT02481674
A Study in Subjects With Late Prodromal & Early Manifest HD to Assess the Safety, Tolerability, pk, and Efficacy of Pepi
Last checked: Nov 19, 2026Latest source record: May 2, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
301
Actual
Start
Jul 2015
Primary completion
Aug 2020
Study completion Aug 2020
Sponsor
- Lead sponsor
- Vaccinex Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Huntington Study Group
- First posted
- Jun 25, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, PK, and efficacy of Pepinemab in subjects with late prodromal and early manifest Huntington's disease.
Conditions
- Huntington's Disease
Interventions
VX15/2503Drug
VX15/2503 (pepinemab) is a humanized IgG4 monoclonal antibody and will be administered intravenously at a dose of 20 mg/kg. The antibody is formulated at 20 mg/mL in 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80.
PlaceboDrug
Placebo consists of formulation buffer only which is 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Revisions to SAP were made prior to un-blinding, on June 30, 2020, upon consultation with FDA.Time frame: Prior to DBL/Study Completion
- Safety and tolerability of monthly intravenous (IV) administration of pepinemab relative to placebo in subjects with early HD (Cohort B pooled, includes Cohort B1 Early Manifest and Cohort B2 Late Prodromal HD).Time frame: Up to 18 months
- Efficacy of monthly IV administration of pepinemab relative to placebo in Early Manifest HD (Cohort B1)Time frame: Up to 18 months
Locations
32 sites in 2 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
University of California, San Diego
La Jolla, California
University of California San Francisco
San Francisco, California
University of Colorado - Denver
Aurora, Colorado
Georgetown University
Washington D.C., District of Columbia
University of Florida Gainesville
Gainesville, Florida
Emory University School of Medicine
Atlanta, Georgia
Indiana University School of Medicine
Indianapolis, Indiana
University of Iowa
Iowa City, Iowa
University of Louisville
Louisville, Kentucky
Johns Hopkins University
Baltimore, Maryland
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Massachusetts General Hospital
Charlestown, Massachusetts
University of Michigan
Ann Arbor, Michigan
Washington University
St Louis, Missouri
Columbia University
New York, New York
Columbia University
New York, New York
University of Rochester
Rochester, New York
Duke University Health Center
Durham, North Carolina
Wake Forest University
Winston-Salem, North Carolina
University of Cincinnati
Cincinnati, Ohio
Ohio State University
Columbus, Ohio
University of Toledo
Toledo, Ohio
Vanderbilt University
Nashville, Tennessee
University of Texas Houston Medical School
Houston, Texas
University of Vermont
Burlington, Vermont
Virginia Commonwealth University
Richmond, Virginia
University of Washington and VA Puget Sound Health Care System
Seattle, Washington
University of Washington
Seattle, Washington
University of Alberta
Edmonton, Alberta, Canada
University of British Columbia
Vancouver, British Columbia, Canada
Centre hospitalier de l'Université de Montréal (CHUM)
Montreal, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.